Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19

Fougerousse, A.‐C.; Perrussel, M.; Becherel, Pierre-André; Bégon, É.; Pallure, V.; Zarâa, I.; Chaby, G.; Parier, J.; Kemula, M.; Méry‐Bossard, L.; Poreaux, C.; Taïeb, C.; Maccari, F.; Réguiai, Z.

doi:10.1111/jdv.16761

Cited by 35 publications

(44 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…16 Given its immunomodulatory properties and its specific mechanism of action, 12,14,16 apremilast does not favor neither the infections nor the cytokines storm, and it will not increase the risk of pulmonary fibrosis, one of the COVID-19's mortality factors. 9 It has been reported that apremilast, as other systemic and biologic therapies, did not increase the risk of severe COVID-19 in psoriasis 17 and psoriatic arthritis 9 patients. Therefore, apremilast where apremilast and acitretin are the only two drugs proposed by the authors to continue or initiate psoriasis therapy.…”

Section: Discussionmentioning

confidence: 98%

COVID ‐19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain

Queiró

Armesto

Vela

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Immunosuppressive and immunomodulatory treatments are critical for the management of inflammatory and autoimmune conditions such as psoriasis or psoriatic arthritis. Like in those illnesses, the lung injury and acute respiratory distress shown in COVID‐19 patients are the result of a disruption in the balance of pro‐ and anti‐inflammatory cytokines. This hyperinflammatory response to SARS‐CoV‐2, associated with the severity of the coronavirus disease, is called the cytokine storm. There is a growing concern regarding how patients on immunosuppressant biologic therapies might be at higher risk of being infected and whether they need to discontinue their treatment preemptively. Clinical data on COVID‐19 infected patients with psoriasis or psoriatic arthritis are still scarce. Here, we presented seven cases of this type of patients. The patient infected with COVID‐19 on apremilast and the one on apremilast with infected spouse showed the best safety profile and mildest symptoms. One of the secukinumab patients also presented a relatively good outcome. Infliximab patients and the one with serious comorbidities showed the worst outcome. Even though more clinical data are yet needed to draw strong conclusions, apremilast could be a safer alternative for dermatology and rheumatology patients in case of clinically important active infection. This article is protected by copyright. All rights reserved.

show abstract

Section: Discussionmentioning

confidence: 98%

COVID ‐19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain

Queiró

Armesto

Vela

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Only 12 patients had PCR confirmed COVID-19 with an additional 54 having probable disease. Five patients were admitted, three of which went to ICU none died 32 .…”

Section: Data From Other Specialtiesmentioning

confidence: 99%

Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes

Grainger

Machado

Robinson

2021

Best Practice & Research Clinical Rheumatology

View full text Add to dashboard Cite

There is concern that people with rheumatic disease, often treated with immunosuppressive or immunomodulatory medication, may be at increased risk of poor outcomes of novel coronavirus disease-2019 (COVID-19). However, hyperinflammation is a major cause of morbidity and mortality in COVID-19 and treatment with glucocorticoids has been shown to improve outcomes in patients with severe COVID-19. Therefore, uncertainty exists about continuing or withholding immune therapies with risk of infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This review covers the current knowledge with respect to risk of infection, and outcomes and risk factors for poor outcomes in patients with rheumatic disease. We also discuss data from other immune mediated diseases and its relevance to patients with rheumatic disease. In addition, we cover the limitations of the research efforts to date and how the current knowledge translates into practice guidance. Finally, we discuss our vision of the future research agenda.

show abstract

“…A number of risk factors for developing severe COVID-19 symptoms have been identified: age, coronary heart disease, diabetes, obesity, and high blood pressure [3] , [4] . However, none of the specific data indicate that there is an increased risk of severe COVID-19 among patients on immunosuppressive treatments [5] , [6] , [7] , [8] . Due to the rapid spread of the pandemic and concerns over the number of deaths, health measures were rapidly implemented: staying home, hygiene protocols, maintaining social distancing of at least 1 meter, etc.…”

Section: Introductionmentioning

confidence: 99%

Impact of the COVID-19 pandemic on children with psoriasis

Beytout

Pepiot²,

Maruani

et al. 2021

Annales de Dermatologie et de Vénéréologie

View full text Add to dashboard Cite

Background Children with psoriasis may have been directly impacted by the COVID-19 pandemic and their illness may also have affected their ability to follow preventive measures. Objective To investigate the impact of the COVID-19 pandemic on children with psoriasis. Methods A survey of children (< 18 years) with psoriasis, conducted from June 10 to June 29, 2020. Results In total, 92 children were included: 71.7% had psoriasis lesions at the time of home lockdown while 45.2% were receiving systemic treatments, and two contracted COVID-19. During lockdown, psoriasis worsened in 47.3% of the children and 18.8% stopped their systemic treatments, mainly for reasons linked to the pandemic. A total of 41.3% had a consultation for psoriasis during lockdown (71.1% by teleconsultation): 39.5% due to worsening of their psoriasis and 21.1% for pandemic-related issues. Among patients not having a consultation during lockdown, 27.5% had a cancellation by the doctor and 9.3% had concerns over going to see the doctor. Finally, 22.8% of patients reported finding it difficult to respect hygiene measures because of their psoriasis, e.g., application of alcohol-based hand sanitizers (47.6%), handwashing routines (42.9%), and wearing a mask (28.6%). Conclusions This study demonstrates the major clinical impact of the COVID-19 pandemic on children with psoriasis. Teleconsultations played a key role in patient management as regards patient monitoring, provision of information, and renewal of treatments. It is vital that we learn from these data to improve and adapt the monitoring of chronic dermatoses in both children and adults in the event of a future health crisis.

show abstract

Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19

Abstract: 4 Russo A, Curtis S, Balbuena-Merle R et al. Bullous hemorrhagic dermatosis is an under-recognized side effect of full dose low-molecular weight heparin: a case report and review of the literature.

Cited by 35 publications

References 6 publications

COVID ‐19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain

COVID ‐19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain

Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes

Impact of the COVID-19 pandemic on children with psoriasis

Contact Info

Product

Resources

About